Post-Approval Prescribing-Information Changes: PAS vs. CBE and SPL Submission Expectations

FDA post-approval prescribing-information changes: PAS vs CBE, and SPL submission expectations

Once an NDA, ANDA, or BLA is approved, the labeling is a locked, approved condition of the application (the reporting categories below are those of 21 CFR 314.70 for NDAs and ANDAs; BLAs follow the parallel structure of 21 CFR 601.12). Any later change to the prescribing information has to move through one of FDA's reporting categories, and the category dictates the single question sponsors care about most: can product bearing the new labeling ship now, or only after FDA signs off? This article lays out how FDA sorts those changes into prior-approval supplements (PAS) and changes-being-effected (CBE-30 and CBE-0) supplements, the narrower set of changes that are merely annual-reportable, the FDA-ordered safety labeling change track under section 505(o)(4), and the Structured Product Labeling (SPL) expectations that now attach to essentially every content-of-labeling submission.

The risk-based framework

FDA places post-approval changes that go beyond the variations already provided for in an approved application into three risk-based tiers: major, moderate, and minor. The tier turns on the change's potential to adversely affect the drug product's identity, strength, quality, purity, or potency as those attributes relate to safety or effectiveness. Critically, the category is set by potential risk, not by the applicant's after-the-fact conclusion that its own data show no adverse effect ⁴⁷⁴³.

A few principles govern how the tiers are applied in practice:

• Except for editorial changes to previously submitted information (spelling or typographical corrections, batch-record reformatting, and the like), the applicant must notify FDA of each change to an established condition in the approved application that falls outside the variations the application already provides for ³⁵.
• The applicant must assess the effect of any change before distributing product made with it; supporting data must exist before distribution, including for annual-reportable changes ⁴³.
• Because the category is fixed by potential for adverse effect, a change FDA recommends be submitted as a supplement does not drop to annual-reportable merely because the applicant's data show no adverse effect ⁴³.
• If the applicant's assessment shows a change actually has adversely affected one of the relevant quality attributes, FDA recommends a PAS regardless of the otherwise-applicable category ⁴².
• Every change must be fully described, with a list of changes in the supplement cover letter or the annual-report summary, in enough detail for FDA to judge whether the chosen category is appropriate ³⁵⁴⁴.

PAS versus CBE for labeling changes

For prescribing-information changes specifically, the pivotal distinction is whether the change qualifies for a CBE supplement under 21 CFR 314.70(c)(6)(iii) for NDAs and ANDAs, or the parallel categories in 21 CFR 601.12(f) for BLAs. A CBE (including CBE-0) supplement is appropriate only for labeling changes that reflect newly acquired information and that:

1. add or strengthen a contraindication, warning, precaution, or adverse reaction, where there is reasonable evidence of a causal association meeting the standard in 21 CFR 201.57(c);
2. add or strengthen a statement about abuse, dependence, psychological effect, or overdosage;
3. add or strengthen a dosage-and-administration instruction intended to increase safe use;
4. delete a false, misleading, or unsupported indication for use or effectiveness claim; or
5. are changes that would ordinarily require prior approval but that FDA specifically requests be submitted as a CBE ¹⁵.

Illustrative examples FDA cites include adding an adverse event reported to the applicant or FDA, adding a precaution arising from a postmarketing study, and clarifying administration instructions to assure proper administration ⁴⁵.

The practical payoff of qualifying for a CBE is timing. For a qualifying CBE/CBE-0 labeling change, the manufacturer may distribute product with the changed labeling upon FDA's receipt of the supplement; prior FDA approval is not required. The supplement still goes through review, and FDA may either approve it or issue a deficiency letter ¹²⁴. FDA will not, however, allow a labeling change that would misbrand the product, for example adding a warning absent reasonable evidence of an association between the drug and the adverse event ¹.

A prior-approval supplement is required for labeling changes that fall outside the CBE categories and outside the annual-report categories. A PAS must be submitted and approved by FDA before product bearing the change is distributed ¹².

The Highlights limitation

One boundary is easy to miss: changes to the Highlights of Prescribing Information under 21 CFR 201.57(a) are not CBE-eligible and require a PAS under 21 CFR 314.70(b)(2)(v)(C), apart from the specific annual-report items that paragraph carves out ¹. Substantive Highlights revisions therefore route to a PAS even when the corresponding full-labeling change might otherwise have been CBE-eligible.

Changes that are merely annual-reportable

Some labeling changes are minor enough to be documented in the next annual report rather than submitted as a CBE or PAS. These include editorial or similar minor changes; product-description information; and how-supplied information that does not change dosage strength or dosage form ⁵. Also annual-reportable: package or container-label layout changes consistent with FDA regulations that do not change labeling content, adding a distributor name, foreign-language labeling where the approved content is unchanged and a certified translation is provided, and labeling changes made to comply with an official compendium ⁵.

Two cautions apply. For nonprescription products, FDA's draft guidance states that changes to Drug Facts Label content generally are not minor and generally may not go in an annual report; and multiple individually minor labeling changes can cumulatively impair consumer understanding or self-selection, in which case a supplement, not an annual report, is appropriate ⁴⁰. FDA can also later determine that an annual-report labeling classification was wrong and request the correct supplement category ⁴⁰.

When a labeling CBE supplement is submitted under § 314.70(c)(6)(iii), the content of labeling is submitted in SPL format, while carton and container final printed labeling is provided as 12 paper copies or a single PDF under FDA's electronic-submission guidance ³⁵⁵. Where the appropriate category is genuinely uncertain, the risk-based potential-for-adverse-effect standard controls, and sponsors should discuss the classification with FDA ⁵⁴³⁴².

FDA-ordered safety labeling changes under section 505(o)(4)

Separate from sponsor-initiated changes, section 505(o)(4) of the FD&C Act lets FDA require a safety labeling change when it becomes aware of new safety information it believes should be in the labeling, including information about a serious or unexpected serious risk (which may rest on a new analysis of existing data) or on REMS effectiveness ⁶⁷. FDA opens the process with a notification letter that identifies the source and description of the new safety information, the proposed labeling changes, and whether the response should be a PAS or a CBE-0 ².

The timeline runs as follows:

• Applicant's initial response (30 days). Within 30 calendar days of the notification letter, the holder must either submit a labeling supplement proposing changes that reflect the new safety information or submit a rebuttal statement explaining why a change is not warranted ⁶¹. If the holder's proposed language is identical to FDA's, it may submit a CBE-0; if it proposes alternative language, it generally should submit a PAS ⁶¹.
• Discussion period and extension. FDA may extend the discussion period beyond 30 days when warranted, usually by another 30 days, and generally does not expect more than one extension ⁷¹.
• Order. FDA may issue an order to make the change if, after the discussion period, it concludes the proposed changes do not adequately address the new safety information, finds the rebuttal rationale unacceptable, or the holder failed to respond within 30 days ⁶⁴⁷¹. FDA intends to issue the order within 15 calendar days after the discussion period (or extension) ends ⁶⁴.
• Post-order supplement (15 days). The order directs the holder to submit a CBE-0 supplement within 15 calendar days of the order date, using FDA-specified wording where provided ⁶⁴. Instead of submitting, the holder may initiate formal dispute resolution within 5 calendar days of the order date ⁶⁴⁶⁶. A holder that does neither violates the statute and risks enforcement ⁶⁶. FDA generally intends to approve an adequately responsive ordered CBE-0 supplement within 15 calendar days of receipt ⁶⁶.

FDA's safety-labeling-change notification letters, in short, tell the application holder both what to submit and under which category, so the PAS-versus-CBE choice in this track is partly directed rather than left to the sponsor ².

SPL submission expectations

Whatever the reporting category, the labeling content itself now has to be submitted electronically in Structured Product Labeling (SPL) format. "Content of labeling" here means the professional labeling/package insert required under 21 CFR 201.100(d)(3), including all text, tables, and figures, and the SPL expectation applies to NDA, ANDA, and applicable BLA content of labeling submitted with original applications, supplements, and annual reports ¹⁵.

Key expectations:

• When SPL is required. An SPL file must accompany all submissions proposing a content-of-labeling change, including certain amendments, for example an amendment to a CBE supplement that includes updated content of labeling. SPL must also accompany submission of the final approved content of labeling, regardless of marketing date, and annual reports ⁹. FDA's stated implementation dates were October 31, 2005 for CDER-regulated products and October 15, 2008 for CBER-regulated products, from which point SPL/XML was expected for content of labeling submitted with original submissions, supplements, and annual reports ⁹¹³.
• Draft and final SPL timing. The proposed labeling change is submitted as the draft SPL with the application or supplement. Where labeling is approved based on that draft SPL, FDA recommends submitting the final SPL preferably within 14 calendar days after approval, or as soon as possible thereafter ¹⁴.
• What belongs in SPL, and what does not. Submit only the electronic content of labeling in SPL, meaning the XML document plus associated image files referenced in the XML (such as chemical structures or clinical-study graphs). Do not use SPL for annotated labeling, container labels, or carton labels ⁹. Approved patient labeling, including Patient Package Inserts and Medication Guides, should be included at the end of the SPL file with the appropriate separate LOINC codes ¹².
• Relationship to other labeling files. SPL content of labeling does not replace the requirement to provide copies of labels and labeling, including final printed labeling. FDA's guidance directs applicants to submit either 12 paper copies or one PDF of the FPL carton/container labels, but only SPL files for the content of labeling submitted with the application ¹⁴. FDA also recommended continuing to submit Word versions to facilitate exchange of comments and revisions, while no longer submitting content of labeling in PDF ¹⁴.
• Avoiding duplicate submissions. If identical content of labeling was already submitted as an SPL through drug establishment registration and listing, FDA's draft Q&A says the applicant need not resubmit that SPL in the application; instead, it recommends placing a link in the application submission referencing the listing SPL ⁹. FDA similarly encouraged applicants to use the registration-and-listing system for labeling and updates and to reference that SPL in application labeling updates rather than make duplicative submissions ¹⁸.

The net effect is that the reporting category (PAS, CBE-30, CBE-0, or annual report) determines the regulatory pathway and distribution timing, while SPL governs the electronic form the labeling content must take on the way in. A sponsor evaluating a prescribing-information change should resolve both questions in parallel: which supplement category the change requires under the risk-based standard, and how the revised content of labeling will be packaged and timed as an SPL submission.